Stock Events

Stock Events

Geovax Labs 

$1.37
0
-$0.06-4.2% Wednesday 07:54

Statistics

Day High
1.41
Day Low
1.37
52W High
-
52W Low
-
Volume
10
Avg. Volume
-
Mkt Cap
40.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Next
-7.75
-6.38
-5.01
-3.64
Expected EPS
-3.63625
Actual EPS
N/A

Financials

-631.91%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
7.91MRevenue
-49.98MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GOVX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to GeoVax's focus area.
Moderna
MRNA
Mkt Cap10.61B
Moderna is involved in mRNA-based vaccines, competing in the same space as GeoVax with its focus on innovative vaccine technologies.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes with GeoVax in the development of vaccines for infectious diseases, including COVID-19, leveraging mRNA technology.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the vaccine market, including efforts against diseases targeted by GeoVax.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, with its global presence and vaccine portfolio, including a COVID-19 vaccine developed with BioNTech, is a competitor in the vaccine space.
Inovio Pharmaceuticals
INO
Mkt Cap124.89M
Inovio Pharmaceuticals focuses on DNA medicines, including vaccines for infectious diseases, positioning it as a competitor to GeoVax.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, with a broad portfolio of vaccines, competes in the same market as GeoVax, targeting various infectious diseases.
Sanofi
SNY
Mkt Cap124.45B
Sanofi, through its vaccine division Sanofi Pasteur, is a major player in the vaccine market, competing with GeoVax in several areas.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma is involved in the development of therapeutic solutions for infectious diseases, indirectly competing with GeoVax's vaccine development efforts.

About

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Show more...
CEO
ISIN
US3736787058

Listings

BOATS
BOATS
GOVX.BOATS
XNAS
US
GOVX

0 Comments

Share your thoughts

FAQ

What is Geovax Labs stock price today?▼
The current price of GOVX.BOATS is $1.37 USD — it has decreased by -4.2% in the past 24 hours. Watch Geovax Labs stock price performance more closely on the chart.
What is Geovax Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Geovax Labs stocks are traded under the ticker GOVX.BOATS.
What is Geovax Labs market cap?▼
Today Geovax Labs has the market capitalization of 40.7M
When is the next Geovax Labs earnings date?▼
Geovax Labs is going to release the next earnings report on April 30, 2026.
What were Geovax Labs earnings last quarter?▼
GOVX.BOATS earnings for the last quarter are -7.75 USD per share, whereas the estimation was -5.85 USD resulting in a -32.42% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Geovax Labs revenue for the last year?▼
Geovax Labs revenue for the last year amounts to 7.91M USD.
What is Geovax Labs net income for the last year?▼
GOVX.BOATS net income for the last year is -49.98M USD.
When did Geovax Labs complete a stock split?▼
Geovax Labs has not had any recent stock splits.